Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26364935 | 0.86 | ELANE (0.44) | SMN1; SMN2ELANENPC1RAB9AHTT | |
| SCHEMBL11411608 | 0.85 | KMT2A (0.44) | MAPTSMN1; SMN2ELANEGRM2NPC1 | |
| SCHEMBL26238738 | 0.85 | LMNA (0.47) | MAPTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL11403410 | 0.84 | KMT2A (0.43) | MAPTSMN1; SMN2ELANEGRM2NPC1 | |
| SCHEMBL11404298 | 0.84 | KMT2A (0.43) | MAPTSMN1; SMN2ELANEGRM2NPC1 | |
| SCHEMBL11411016 | 0.84 | F2 (0.46) | MAPTSMN1; SMN2ELANEGAAHTT | |
| SCHEMBL11418148 | 0.84 | KMT2A (0.43) | MAPTSMN1; SMN2ELANEGRM2NPC1 | |
| SCHEMBL10932380 | 0.84 | ELANE (0.48) | MGLLMAPTSMN1; SMN2ELANENPC1 | |
| SCHEMBL10932384 | 0.84 | ELANE (0.48) | MGLLMAPTSMN1; SMN2ELANENPC1 | |
| SCHEMBL25502752 | 0.84 | ELANE (0.48) | MGLLMAPTSMN1; SMN2ELANENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621958-B1 | PHOTOCHROMIC INDENO FUSED PHENANTHRENOPYRAN COMPOUNDS | TRANSITIONS OPTICAL LTD (IE) | 2024-07-10 | — | — | EP | disclosed |
| EP-3268375-B1 | PHOTOCHROMIC THIENOCHROMENE COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3071576-B9 | PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3071576-B1 | PHOTOCHROMIC INDENO-FUSED RING PYRAN COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20200048216-A1 | Photochromic Indeno Fused Phenanthrenopyran Compounds | TRANSITIONS OPTICAL, LTD. (IE) | 2020-02-13 | — | — | US | disclosed |
| EP-2970760-B1 | PHOTOCHROMIC ARTICLES THAT INCLUDE PHOTOCHROMIC-DICHROIC MATERIALS | TRANSITIONS OPTICAL INC (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3071550-B1 | METHOD OF PREPARING FUSED RING INDENO COMPOUNDS | TRANSITIONS OPTICAL INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9309455-B2 | Indeno-fused ring compounds | TRANSITIONS OPTICAL, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309455-B2 | Indeno-fused ring compounds | TRANSITIONS OPTICAL, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140166948-A1 | INDENO-FUSED RING COMPOUNDS | TRANSITIONS OPTICAL LIMITED (IE) | 2014-06-19 | — | — | US | disclosed |
| US-20140166948-A1 | INDENO-FUSED RING COMPOUNDS | TRANSITIONS OPTICAL LIMITED (IE) | 2014-06-19 | — | — | US | disclosed |
| US-20120126185-A1 | INDENO-FUSED RING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120126185-A1 | INDENO-FUSED RING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048216-A1 | Photochromic Indeno Fused Phenanthrenopyran Compounds | ALDH1A2, RB1, INCENP | MGLL 4818/4885MAPT 1822/4885SMN1; SMN2 4769/4885 |
| US-20120126185-A1 | INDENO-FUSED RING COMPOUNDS | CRY2, SQOR, INTS6 | MGLL 4769/4885MAPT 2624/4885SMN1; SMN2 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.